Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial
Nature Medicine – In participants with obesity and chronic kidney disease without diabetes, once-weekly administration of semaglutide 2.4โmg led to a reduction in albuminuria, body weight and…